Economic Burden of Parkinson's Disease: A Multinational, Real-World, Cost-of-Illness Study
- PMID: 38193999
- PMCID: PMC10928026
- DOI: 10.1007/s40801-023-00410-1
Economic Burden of Parkinson's Disease: A Multinational, Real-World, Cost-of-Illness Study
Abstract
Background: Parkinson's disease is now one of the fastest-growing neurodegenerative disorders in the developed world, with an increasing prevalence and associated socioeconomic costs. Progression of the disease leads to a gradual deterioration in patients' quality of life, despite optimal treatment, and both medical and societal needs increase, often with the assistance of paid and/or unpaid caregivers.
Objective: We aimed to quantify the incremental economic burden of Parkinson's disease by disease severity in a real-world setting across differing geographic regions.
Methods: Demographics, clinical characteristics, health status, patient quality of life, caregiver burden, and healthcare resource utilization data were drawn from the Adelphi Parkinson's Disease Specific Program™, conducted in the USA, five European countries, and Japan.
Results: A total of 563 neurologists provided data for 5299 individuals with Parkinson's disease; 61% were male, with a mean age of 64 years. Approximately 15% of individuals were deemed to have advanced disease, with significantly more comorbidities, and a poorer quality of life, than those with non-advanced disease. Overall, the mean annual healthcare resource utilization increased significantly with advancing disease, and resulted in a three-fold difference in the USA and Europe. The main drivers behind the high economic burden included hospitalizations, prescription medications, and indirect costs.
Conclusions: People with Parkinson's disease, and their caregivers, incur a higher economic burden as their disease progresses. Future interventions that can control symptoms or slow disease progression could reduce the burden on people with Parkinson's disease and their caregivers, whilst also substantially impacting societal costs.
© 2024. The Author(s).
Conflict of interest statement
K. Ray Chaudhuri has received honoraria for lectures from AbbVie, Britannia, UCB, Zambon, Novartis, Boehringer Ingelheim, and Bial; has taken part in advisory boards for and acted as a consultant for AbbVie, UCB , GKC, Bial, Cynapsus, Lobsor, Stada, Medtronic, Zambon, Profile, Sunovion, Roche, Therevance, Scion, Britannia, Acadia, and 4D; and has received grants for investigator-initiated research from Britannia Pharmaceuticals, AbbVie, UCB, GKC, and Bial, and academic grants from EU, IMI EU, Horizon 2020, Parkinson’s UK, NIHR, Parkinson’s disease NMG, EU (Horizon 2020), Kirby Laing Foundation, NPF, MRC, and Wellcome Trust. Per Odin has received honoraria for lectures and advice from Britannia, Bial, Ever Pharma, Nordic Infucare, and Zambon, and has received honoraria for lectures and advice as well as research grants from AbbVie. Jean-Philippe Azulay, Susanna Lindvall, and J Josefa Domingos have no conflicts of interest that are directly relevant to the content of this article. Ali Alobaidi, Prasanna L. Kandukuri, Juan Carlos Parra, and Toru Yamazaki are employees of AbbVie and may own stocks/shares in the company. Vivek S. Chaudhari is a former employee of AbbVie Inc., currently employed by EMD Serono, Inc. and may hold AbbVie stock. Julia Oddsdottir is an employee of IQVIA, which received consultancy fees from AbbVie. Jack Wright is an employee of Adelphi Real World, a consulting company that was hired by AbbVie to perform analyses on the Adelphi Disease Specific Program database. Pablo Martinez-Martin has received honoraria from Bial, for participation in a course, and from the International Parkinson and Movement Disorder Society for activities during the International Congress 2023 and for directing the Clinical Outcome Assessment Program.
Figures
References
LinkOut - more resources
Full Text Sources
